Manulife (Manufacturers Life Insurance)
PHAT icon

Manulife (Manufacturers Life Insurance)’s Phathom Pharmaceuticals PHAT Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$143K Buy
12,908
+470
+4% +$5.94K ﹤0.01% 2543
2025
Q4 		$206K Sell
12,438
-2,174
-15% -$31K ﹤0.01% 2513
2025
Q3 		$172K Sell
14,612
-1,214
-8% -$12.5K ﹤0.01% 2633
2025
Q2 		$152K Buy
15,826
+1,364
+9% +$7.55K ﹤0.01% 2652
2025
Q1 		$90.7K Buy
14,462
+472
+3% +$2.87K ﹤0.01% 2717
2024
Q4 		$114K Buy
13,990
+396
+3% +$4.9K ﹤0.01% 2793
2024
Q3 		$246K Sell
13,594
-347
-2% -$4.85K ﹤0.01% 2571
2024
Q2 		$144K Buy
13,941
+1,339
+11% +$13.8K ﹤0.01% 2724
2024
Q1 		$134K Buy
12,602
+352
+3% +$2.99K ﹤0.01% 2716
2023
Q4 		$112K Hold
12,250
– – ﹤0.01% 2784
2023
Q3 		$127K Buy
12,250
+1,834
+18% +$25.2K ﹤0.01% 2731
2023
Q2 		$149K Buy
+10,416
New +$120K ﹤0.01% 2716
2022
Q4 		– Sell
-10,080
Closed -$112K – 2992
2022
Q3 		$112K Sell
10,080
-404
-4% -$3.85K ﹤0.01% 2782
2022
Q2 		$88.5K Buy
+10,484
New +$108K ﹤0.01% 2947
2022
Q1 		– Sell
-11,443
Closed -$225 – 3163
2021
Q4 		$225 Buy
11,443
+253
+2% +$5.95K ﹤0.01% 2827
2021
Q3 		$359K Sell
11,190
-699
-6% -$23.2K ﹤0.01% 2535
2021
Q2 		$402K Buy
11,889
+4,765
+67% +$171K ﹤0.01% 2586
2021
Q1 		$268K Buy
7,124
+267
+4% +$11.2K ﹤0.01% 2684
2020
Q4 		$228K Buy
6,857
+113
+2% +$4.58K ﹤0.01% 2698
2020
Q3 		$247K Hold
6,744
– – ﹤0.01% 2432
2020
Q2 		$227K Buy
+6,744
New +$259K ﹤0.01% 2433

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s PHAT Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) increased its Phathom Pharmaceuticals (PHAT) stake by 3.8% in Q1 2026, buying an estimated $5.94K and bringing the position to 12,908 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #2543.

Manulife (Manufacturers Life Insurance) first reported a position in PHAT in Q2 2020 and has held it in 21 quarters since. The position peaked at $402K in Q2 2021. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 12,908 shares of Phathom Pharmaceuticals worth $143K as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) bought 470 Phathom Pharmaceuticals shares in Q1 2026, an estimated $5.94K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #2543 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Phathom Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Phathom Pharmaceuticals position peaked at $402K in Q2 2021.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.